The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
An anti-ER “Riptac” enters phase 1.
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
BeOne's degrader BG-60366 appears to have been discontinued.
